TY - JOUR
T1 - Magnitude of Off-Target Allo-HLA Reactivity by Third-Party Donor-Derived Virus-Specific T Cells Is Dictated by HLA-Restriction
AU - Huisman, Wesley
AU - Leboux, Didier A. T.
AU - van der Maarel, Lieve E.
AU - Hageman, Lois
AU - Amsen, Derk
AU - Falkenburg, J. H. Frederik
AU - Jedema, Inge
N1 - Funding Information: The authors thank the Sanquin Bloodbank donors that were willing to donate and the Flow Cytometry Facility of the LUMC for the significant number of cell-sorts they performed. Funding. This work was supported by Sanquin Research and Landsteiner Laboratory for Blood Cell research (PPO 15-37/Lnumber 2101). This study was in part also supported by research funding from Stichting den Brinker (The Netherlands, Zeist) that made a donation to the Leukemia fund from the Bontius Foundation (Leiden University Medical Center). These sponsors are non-profit organizations that supports science in general. They had no role in gathering, analyzing, or interpreting the data. Publisher Copyright: © Copyright © 2021 Huisman, Leboux, van der Maarel, Hageman, Amsen, Falkenburg and Jedema.
PY - 2021/3/29
Y1 - 2021/3/29
N2 - T-cell products derived from third-party donors are clinically applied, but harbor the risk of off-target toxicity via induction of allo-HLA cross-reactivity directed against mismatched alleles. We used third-party donor-derived virus-specific T cells as model to investigate whether virus-specificity, HLA restriction and/or HLA background can predict the risk of allo-HLA cross-reactivity. Virus-specific CD8pos T cells were isolated from HLA-A*01:01/B*08:01 or HLA-A*02:01/B*07:02 positive donors. Allo-HLA cross-reactivity was tested using an EBV-LCL panel covering 116 allogeneic HLA molecules and confirmed using K562 cells retrovirally transduced with single HLA-class-I alleles of interest. HLA-B*08:01-restricted T cells showed the highest frequency and diversity of allo-HLA cross-reactivity, regardless of virus-specificity, which was skewed toward multiple recurrent allogeneic HLA-B molecules. Thymic selection for other HLA-B alleles significantly influenced the level of allo-HLA cross-reactivity mediated by HLA-B*08:01-restricted T cells. These results suggest that the degree and specificity of allo-HLA cross-reactivity by T cells follow rules. The risk of off-target toxicity after infusion of incompletely matched third-party donor-derived virus-specific T cells may be reduced by selection of T cells with a specific HLA restriction and background.
AB - T-cell products derived from third-party donors are clinically applied, but harbor the risk of off-target toxicity via induction of allo-HLA cross-reactivity directed against mismatched alleles. We used third-party donor-derived virus-specific T cells as model to investigate whether virus-specificity, HLA restriction and/or HLA background can predict the risk of allo-HLA cross-reactivity. Virus-specific CD8pos T cells were isolated from HLA-A*01:01/B*08:01 or HLA-A*02:01/B*07:02 positive donors. Allo-HLA cross-reactivity was tested using an EBV-LCL panel covering 116 allogeneic HLA molecules and confirmed using K562 cells retrovirally transduced with single HLA-class-I alleles of interest. HLA-B*08:01-restricted T cells showed the highest frequency and diversity of allo-HLA cross-reactivity, regardless of virus-specificity, which was skewed toward multiple recurrent allogeneic HLA-B molecules. Thymic selection for other HLA-B alleles significantly influenced the level of allo-HLA cross-reactivity mediated by HLA-B*08:01-restricted T cells. These results suggest that the degree and specificity of allo-HLA cross-reactivity by T cells follow rules. The risk of off-target toxicity after infusion of incompletely matched third-party donor-derived virus-specific T cells may be reduced by selection of T cells with a specific HLA restriction and background.
KW - Graft Versus Host Disease
KW - HLA-mismatched donor
KW - adoptive T cell immunotherapy
KW - allo-HLA cross-reactivity
KW - cytotoxic T cells
KW - virus-specific T cells
UR - http://www.scopus.com/inward/record.url?scp=85104016183&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fimmu.2021.630440
DO - https://doi.org/10.3389/fimmu.2021.630440
M3 - Article
C2 - 33854504
SN - 1664-3224
VL - 12
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 630440
ER -